Use of Hydroxychloroquine
AHS is connecting with clinicians, operations, researchers and other experts to review emerging evidence and guidance of national and international bodies to ensure we have the most current information to provide care to Albertans during this pandemic.
At this time, Hydroxychloroquine is not recommended to be used as prophylaxis for COVID-19 outside clinical trials, given the lack of established benefit (with no existing data on prophylaxis) to counterbalance potential harms. There is minimal evidence for hydroxychloroquine in use as prophylaxis for COVID-19 illness. There are multiple trials underway to explore this, including determining what groups would be considered at highest risk and therefore in need of prophylaxis.
Potential harms of hydroxychloroquine include serious clinical and laboratory adverse effects, potential drug interactions, and pediatric morbidity and mortality. We will continue to monitor the research and evidence for hydroxychloroquine. More information is available
here.